Mirvie Raises $60M To Develop Early Preeclampsia Detection And More Digital Health Fundings

Also: Nurse practitioner support startup Greater Good Health raises $10 million, and care coordination platform ThoroughCare scoops up $3 million.

Mirvie, which is developing a blood test that aims to identify risk of preeclampsia before symptoms occur, raised $60 million in Series B funding.

The round was led by Decheng Capital with participation from funds managed by BlackRock, Foresite Capital, General Catalyst, GV, Khosla Ventures, Mayfield and Olympic gold-medalist Allyson Felix. It also included a debt facility with Comerica Bank. 

Mirvie announced it had received Breakthrough Device Designation for its preeclampsia test earlier this month. The startup is also studying using its RNA platform to predict preterm births. 

"Mirvie is a trailblazer in a field desperate for innovation to address the often devastating and costly lifetime consequences of pregnancy complications," Min Cui, founder and managing director of Decheng Capital, said in a statement. "This funding syndicate is committed to supporting Mirvie’s objective to provide clinicians, expecting parents and babies with breakthrough innovation that makes what is impossible today into a reality."

Nurse practitioner support platform Greater Good Health raised $10 million in a funding round led by LRVHealth.

Other participants in the round include Martin Ventures, Health Velocity Capital and Optum Ventures as well as angel investors. Greater Good's platform includes tools for scheduling, professional development, wellness and stress management, and networking with other nurse practitioners. It launched out of stealth in December, and has now raised $13 million in total funding.